Mandelia Ashish

VP, Chief Accounting OfficerMersana Therapeutics, Inc. (MRSN) · full profile →Form 4 · filed Jan 17, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2K
Net Open-Market Flow
-$2K
Transactions
7
3 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 16, 2025Sell(S)4K$0.58$2K58K
Jan 15, 2025Option exercise(M)4K$061K
Jan 15, 2025Option exercise(M)5K$057K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 15, 2025Grant(A)17K$017K
Jan 15, 2025Option exercise(M)4K$013K
Jan 15, 2025Option exercise(M)5K$00
Jan 15, 2025Grant(A)75K$075K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-25-004597) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.